Aurobindo Hits Back Over Sandoz Delay Rumors
Media Reports On FTC Discussions Are ‘Factually Inaccurate’
Executive Summary
Aurobindo has hit back over rumors that completion of its pending transaction to acquire Sandoz’ US dermatology and oral-solids businesses has been delayed until next year over FTC information requests.